Monday morning, Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy. This follows AstraZeneca’s Q2 report released on July 29 that included several other drugs and trials the company is axing.
Tag Archive for: squamous cell carcinoma of the head and neck (SCCHN)
Shares of MacroGenics, Inc. are falling in pre-market trading after the company announced late Friday that it has shuttered a Phase II study of its investigational drug enoblituzumab as part of a combination therapy for head and neck cancer following seven reported deaths.
